Global Gene Therapy For Retinal Diseases Market

Report ID : 1157 | Published : 2021-07-27 | Pages: 140 | Format:

Gene therapy states a method of announcing foreign DNA constructs into host cells in demand to treat various medical conditions, including retinal diseases. Gene therapy has an increasing research potential, mainly in the arena of retinal and ophthalmic diseases. The main features of the eye include convenience in terms of surgical interventions and injections and fitted blood-ocular barriers that bar other organs from undesirable contamination. The high potential of gene therapy to treat ocular diseases is boosting the demand for the market globally. Additionally, the approval of the first gene therapy for retinal diseases in 2017 is expected to increase the demand in the coming years.

The presence of several drugs under clinical trials and their positive results are expected to generate immense opportunities for market growth over the forecast period. The evidence of the use of the gene as a medicine has come a long way and establishes its position in treating retinal disease. Certainly, with only limited availability of treatment options for retinal diseases, gene therapy has been established safe, feasible, and effective and could lead to robust effects after a single injection. The global gene therapy for retinal diseases market size is expected to reach US$ xx million by 2030, growing at a CAGR of xx% over the forecast period. Moreover, growing strategic partnerships and acquisitions among the key players operating in the market are expected to significantly propel market growth. However, the high cost associated with gene therapy may affect the growth of gene therapy in the retinal disease market. However, growing demand for modified and effective treatment and rising research funding globally is estimated to drive the market growth substantially during the estimated time frame.

The Global Gene Therapy for Retinal Diseases Market is segmented on the basis of indication, and region. Based on the indication, the market is divided into Choroideremia (CHM), Leber congenital amaurosis, Leber’s hereditary optic neuropathy, X-linked retinitis pigmentosa, and Other Indication. Based on the region, the market is studied across North America, Asia-Pacific, Europe, and the Rest of the World. North America accounted for the significant share in the gene therapy for retinal disease market, followed by Europe. A large number of research laboratories and biopharmaceutical companies operating in the market are contributing towards the high share of the region in the global market. Additionally, well-established healthcare infrastructure in the U.S. and the high adoption of advanced technologies for treatment are propelling the growth of U.S. gene therapy for the retinal diseases market.

The key players of this market include Applied Genetic Technologies Corporation, Adverum Biotechnologies, ProQR Therapeutics, MeiraGTx Limited., Oxford BioMedica, Horama S.A., Gensight Biologics, Regenxbio Inc., Spark Therapeutics, Inc., Genzyme (Sanofi), Novartis Pharmaceuticals, Nightstar Therapeutics (Biogen), Hemera Biosciences, among Allergan among others. The growing mergers and acquisitions among key players operating in the market are expected to foster market growth significantly in the coming years.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Gene Therapy for Retinal Diseases Market Snapshot

Chapter 4. Global Gene Therapy for Retinal Diseases Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Epidemiology: Incidence Prevalence Analysis 2019

4.6.1. Choroideremia (CHM)

4.6.2. Leber congenital amaurosis

4.6.3. Leber’s hereditary optic neuropathy

4.6.4. Retinitis pigmentosa

4.6.5. X-linked retinitis pigmentosa

4.6.6. X-linked retinoschisis

4.6.7. Usher syndrome type 1B

4.6.8. Stargardt disease

4.6.9. Achromatopsia

4.6.10. Neovascular/age-related macular degeneration

4.7. Clinical Trial/Pipeline Analysis

4.8. Industry Analysis – Porter’s Five Forces Analysis

4.9. Technology Advancement in Gene Therapy for Retinal Diseases Market

Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis

5.1. Indication Type & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Indication:

5.2.1. Choroideremia (CHM)

5.2.2. Leber congenital amaurosis

5.2.3. Leber’s hereditary optic neuropathy

5.2.4. Retinitis pigmentosa

5.2.5. X-linked retinitis pigmentosa

5.2.6. X-linked retinoschisis

5.2.7. Usher syndrome type 1B

5.2.8. Stargardt disease

5.2.9. Achromatopsia

5.2.10. Neovascular/age-related macular degeneration

5.2.11. Other Indication

Chapter 6. Gene Therapy for Retinal Diseases Market Segmentation 3: Regional Estimates & Trend Analysis

6.1. North America

6.1.1. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by Indication, 2020-2030

6.1.2. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

6.1.2.1. U.S.

6.1.2.2. Canada

6.2. Europe

6.2.1. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030

6.2.2. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030

6.2.2.1. Germany

6.2.2.2. Poland

6.2.2.3. France

6.2.2.4. Italy

6.2.2.5. Spain

6.2.2.6. UK

6.2.2.7. Rest of Europe

6.3. Asia Pacific

6.3.1. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030

6.3.2. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030

6.3.2.1. China

6.3.2.2. India

6.3.2.3. Japan

6.3.2.4. Australia

6.3.2.5. Rest of Asia Pacific

6.4. Latin America

6.4.1. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million)

6.4.2. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2030

6.4.2.1. Brazil

6.4.2.2. Rest of Latin America

6.5. MEA

6.5.1. MEA revenue Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million) 2020-2030

Chapter 7. Competitive Landscape

7.1. Major Mergers and Acquisitions/Strategic Alliances

7.2. Company Profiles

7.2.1. Applied Genetic Technologies Corporation

7.2.2. Adverum Biotechnologies

7.2.3. ProQR Therapeutics

7.2.4. MeiraGTx Limited.

7.2.5. Oxford BioMedica

7.2.6. Horama S.A.

7.2.7. Gensight Biologics

7.2.8. Regenxbio Inc.

7.2.9. Spark Therapeutics, Inc.

7.2.10. Genzyme (Sanofi)

7.2.11. Novartis Pharmaceuticals

7.2.12. Nightstar Therapeutics (Biogen)

7.2.13. Hemera Biosciences

7.2.14. ViGeneron GmbH

7.2.15. Allergan

7.2.16. Eyevensys

7.2.17. Clearside Biomedical

7.2.18. IVERIC bio, Inc.

7.2.19. Other Prominent Players

Global Gene Therapy for Retinal Diseases Market Segmentation:

Global Gene Therapy for Retinal Diseases Market by Indication

  • Choroideremia (CHM)
  • Leber congenital amaurosis
  • Leber’s hereditary optic neuropathy
  • X-linked retinitis pigmentosa
  • Other Indication

Global Gene Therapy for Retinal Diseases Market Based on Region

  • Europe
  • Germany
  • Poland
  • France
  • Italy
  • Spain
  • UK
  • Rest of Europe
  • North America
  • U.S.
  • Canada
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia
  • Rest of Asia Pacific
  • Rest of World

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients